Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 73 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Ligand Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ligand Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ligand Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ligand Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Ligand Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Ligand Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ligand Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ligand Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ligand Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ligand Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ligand Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Ligand Pharmaceuticals, Inc. Snapshot 7
Ligand Pharmaceuticals, Inc. Overview 7
Key Information 7
Key Facts 7
Ligand Pharmaceuticals, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Ligand Pharmaceuticals, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Ligand Pharmaceuticals, Inc. - Pipeline Products Glance 17
Ligand Pharmaceuticals, Inc. - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Ligand Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Ligand Pharmaceuticals, Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 22
Ligand Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 23
Unknown Products/Combination Treatment Modalities 23
Ligand Pharmaceuticals, Inc. - Drug Profiles 24
clopidogrel bisulfate 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
MB-07133 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
aplindore fumarate 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MB-07803 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
budesonide 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
LGD-4033 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LGD-6972 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
pradefovir mesylate 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drug Targeting JAK3 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug to Inhibit CCR1 for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Enterocyte-Directed DGAT-1 Inhibitor Program 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
IRAK4 Program 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LG-5640 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
LG-7455 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LG-7501 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LGD-3437 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PS-031291 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Inhibit CRTH2 for Inflammation 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit EPO Receptor for Anemia 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
tanaproget 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Thyroid Receptor-Beta Agonist Program 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
fosphenytoin sodium 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Undisclosed Anti-Inflammatory Program 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Ligand Pharmaceuticals, Inc. - Pipeline Analysis 50
Ligand Pharmaceuticals, Inc. - Pipeline Products by Target 50
Ligand Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 52
Ligand Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 53
Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 54
Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates 56
Ligand Pharmaceuticals, Inc. - Dormant Projects 61
Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products 63
Discontinued Pipeline Product Profiles 63
adipiplon 63
clopidogrel bisulfate 63
LGD-5552 64
managlinat dialanetil 64
NGD-2000-1 64
NGD-91-1 64
NGD-91-2 64
NGD-91-3 64
NGD-94-1 64
NGD-94-4 64
NGD-96-1 65
NGD-97-1 65
Vanilloid Receptor-1 Program 65
Ligand Pharmaceuticals, Inc. - Company Statement 66
Ligand Pharmaceuticals, Inc. - Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Ligand Pharmaceuticals, Inc., Key Information 7
Ligand Pharmaceuticals, Inc., Key Facts 7
Ligand Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9
Ligand Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11
Ligand Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12
Ligand Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 13
Ligand Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
Ligand Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 15
Ligand Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 16
Ligand Pharmaceuticals, Inc. - Phase III, 2014 17
Ligand Pharmaceuticals, Inc. - Phase II, 2014 18
Ligand Pharmaceuticals, Inc. - Phase I, 2014 19
Ligand Pharmaceuticals, Inc. - Preclinical, 2014 20
Ligand Pharmaceuticals, Inc. - Discovery, 2014 22
Ligand Pharmaceuticals, Inc. - Unknown, 2014 23
Ligand Pharmaceuticals, Inc. - Pipeline by Target, 2014 51
Ligand Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 52
Ligand Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 53
Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 55
Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 56
Ligand Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 61
Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 63
Ligand Pharmaceuticals, Inc., Subsidiaries 70